Free Trial

What is HC Wainwright's Estimate for AGIO FY2026 Earnings?

Agios Pharmaceuticals logo with Medical background

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Research analysts at HC Wainwright dropped their FY2026 EPS estimates for Agios Pharmaceuticals in a report issued on Monday, June 9th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of ($8.44) per share for the year, down from their previous estimate of ($8.35). HC Wainwright has a "Buy" rating and a $58.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals' FY2027 earnings at ($9.38) EPS, FY2028 earnings at ($8.48) EPS and FY2029 earnings at ($6.32) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The company had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million.

Several other brokerages have also issued reports on AGIO. Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Scotiabank cut their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $58.60.

Read Our Latest Stock Report on AGIO

Agios Pharmaceuticals Stock Down 0.6%

NASDAQ:AGIO traded down $0.20 during midday trading on Thursday, hitting $34.30. The company had a trading volume of 478,627 shares, compared to its average volume of 662,530. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The stock's fifty day moving average price is $29.76 and its 200-day moving average price is $33.41. The company has a market capitalization of $1.99 billion, a PE ratio of 3.02 and a beta of 0.73.

Insider Transactions at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. raised its stake in Agios Pharmaceuticals by 7.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after buying an additional 394 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 499 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock valued at $450,000 after purchasing an additional 582 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Agios Pharmaceuticals by 1.2% during the fourth quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock valued at $2,021,000 after purchasing an additional 708 shares in the last quarter. Finally, Atria Investments Inc increased its stake in shares of Agios Pharmaceuticals by 6.9% during the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after purchasing an additional 737 shares in the last quarter.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

See Also

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Should You Invest $1,000 in Agios Pharmaceuticals Right Now?

Before you consider Agios Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.

While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines